Related Experiment Video
Updated: Jul 15, 2026

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
Published on: August 14, 2018
MEK1/2 inhibitors block basal and transforming growth factor 1beta1-stimulated JC virus multiplication
Veerasamy Ravichandran1, Peter N Jensen, Eugene O Major
1Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1296, USA.
Abstract:
The multiplication of the human neurotropic polyomavirus JC virus (JCV) is regulated by cell membrane receptors and nuclear transcription factors. Signaling pathways also play a role in determining the extent to which JCV can productively infect cells. These data show that constitutively active MEK1 protein (CA-MEK1), overexpressed in cultures of human glia, supports a substantial increase in late JCV protein (Vp-1) synthesis. The specificity of this pathway was indicated by no significant enhancement of JCV multiplication through activation of other components of mitogen-activated protein kinase pathways such as p38, Jun N-terminal protein kinase, and protein kinase A. Further evidence supporting the importance of signaling in JCV infection came from addition of transforming growth factor beta1 (TGF-beta1), which stimulated a 200% increase of Vp-1 expression. Specific MEK1/2 inhibitors, flavenoid PD98059 and U0126, decreased the basal and TGF-beta1-stimulated Vp-1 expression by 95% or more. TGF-beta1 is known to phosphorylate/activate Smad DNA binding proteins that could subsequently bind or increase binding to JCV promoter sequences, linking the effects of signaling with JCV transcriptional regulation. The effectiveness with which MEK1/2 inhibitors block JCV multiplication provides insight that may contribute to development of compounds directed against JCV.
Insights
Activating the MEK1 pathway significantly boosts JC virus (JCV) replication in human glial cells. Inhibiting MEK1/2 effectively blocks JCV multiplication, suggesting a therapeutic target for JCV infections.
Area of Science:
- Virology
- Molecular Biology
- Cell Signaling
Background:
- JC virus (JCV) multiplication is influenced by cellular factors, including signaling pathways.
- Understanding JCV's regulatory mechanisms is crucial for developing antiviral strategies.
Purpose of the Study:
- To investigate the role of specific mitogen-activated protein kinase (MAPK) pathways in JC virus (JCV) replication.
- To determine if transforming growth factor beta1 (TGF-beta1) impacts JCV infection through signaling cascades.
Main Methods:
- Overexpression of constitutively active MEK1 (CA-MEK1) in human glial cells.
- Assessing JCV late protein (Vp-1) synthesis following pathway activation or inhibition.
- Utilizing MEK1/2 inhibitors (PD98059, U0126) and TGF-beta1 treatment.
Main Results:
- Constitutively active MEK1 significantly increased JCV Vp-1 synthesis.
- TGF-beta1 treatment stimulated a 200% increase in Vp-1 expression.
- MEK1/2 inhibitors reduced basal and TGF-beta1-stimulated Vp-1 expression by over 95%.
Conclusions:
- The MEK1 signaling pathway is a critical regulator of JC virus (JCV) multiplication.
- MEK1/2 inhibitors demonstrate potent antiviral activity against JCV.
- Targeting the MEK1/2 pathway offers a promising therapeutic avenue for JCV infections.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Inhibition of CDK Activity
Inhibition of Cdk Activity
Antiviral Nucleoside Inhibitors

